Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid Long COVID-19 Prevention Trial (Community, Norway)
2022-003244-27Phase 3Active
- Sponsor
- Helse Bergen
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Helse Bergen. Primary endpoint: Continued symptoms and new long COVID symptoms. Started Jan 2023; status: active.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-003244-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003244-27.